We serve Chemical Name:3-(3-bromophenyl)prop-2-yn-1-ol CAS:170859-80-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-(3-bromophenyl)prop-2-yn-1-ol
CAS.NO:170859-80-0
Synonyms:MFCD04039055
Molecular Formula:C9H7BrO
Molecular Weight:211.05500
HS Code:2906299090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:304.2ºC at 760mmHg
Density:1.58g/cm3
Index of Refraction:1.638
PSA:20.23000
Exact Mass:209.96800
LogP:1.79290
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like MFCD04039055 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD04039055 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD04039055 Use and application,MFCD04039055 technical grade,usp/ep/jp grade.
Related News: Mankind Pharmaceuticals on Monday said it has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country. 3-(3-bromophenyl)prop-2-yn-1-ol manufacturer Process: The importance of safety is obvious. The research and development of specialty drug substances (especially high-barrier generic drug substance drugs) usually need to avoid the original process patents, and some chemicals are developed because of the complex structure or the harsh synthetic conditions The synthetic route is more difficult, so the importance of process design capabilities of API companies is becoming more important. 3-(3-bromophenyl)prop-2-yn-1-ol supplier Adding Darzalex to Bristol Myers Squibb’s Revlimid and steroid dexamethasone (Rd) could slash the risk of death by 32% in newly diagnosed multiple myeloma patients ineligible to receive stem cell transplants, J&J reported at the European Hematology Association’s virtual congress. 3-(3-bromophenyl)prop-2-yn-1-ol vendor If the results from that trial are positive, the company might apply to the U.S. Food and Drug Administration for the same accelerated approval pathway recently used to bring the controversial Alzheimer’s drug aducanumab to market, Novak said. 3-(3-bromophenyl)prop-2-yn-1-ol factory API (Active Pharmaceutical Ingredient) means the active ingredient which is contained in medicine.
